

# Jakub Radocha

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4973783/publications.pdf>

Version: 2024-02-01

65  
papers

421  
citations

840119

11  
h-index

887659

17  
g-index

70  
all docs

70  
docs citations

70  
times ranked

764  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. <i>British Journal of Haematology</i> , 2018, 180, 831-839.	1.2	41
2	Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy. <i>PLoS ONE</i> , 2015, 10, e0123866.	1.1	32
3	Hematogenous extramedullary relapse in multiple myeloma – a multicenter retrospective study in 127 patients. <i>American Journal of Hematology</i> , 2019, 94, 1132-1140.	2.0	24
4	Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. <i>Leukemia</i> , 2022, 36, 288-291.	3.3	23
5	Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 1571.	1.7	21
6	Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1372-1378.	2.0	20
7	Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice. <i>BMC Cancer</i> , 2021, 21, 73.	1.1	20
8	The role of intracellular zinc in modulation of life and death of Hep-2 cells. <i>BioMetals</i> , 2003, 16, 295-309.	1.8	19
9	High-dose chemotherapy followed by autologous stem cell transplantation changes prognosis of IgD multiple myeloma. <i>Bone Marrow Transplantation</i> , 2008, 41, 51-54.	1.3	19
10	Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model. <i>British Journal of Haematology</i> , 2020, 190, 189-197.	1.2	13
11	Viridans group streptococci bloodstream infections in neutropenic adult patients with hematologic malignancy: Single center experience. <i>Folia Microbiologica</i> , 2018, 63, 141-146.	1.1	11
12	A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. <i>American Journal of Hematology</i> , 2020, 95, 503-509.	2.0	11
13	Registry of Monoclonal Gammopathies (RMG) in the Czech Republic. <i>Blood</i> , 2015, 126, 4514-4514.	0.6	11
14	Association Study of Selected Genetic Polymorphisms and Occurrence of Venous Thromboembolism in Patients With Multiple Myeloma Who Were Treated With Thalidomide. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 414-420.	0.2	10
15	Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment. <i>European Journal of Haematology</i> , 2007, 79, 305-309.	1.1	9
16	Prediction of Progression of Smouldering into Therapy Requiring Multiple Myeloma By Easily Accessible Clinical Factors [in 527 Patients]. <i>Blood</i> , 2014, 124, 2071-2071.	0.6	9
17	Outcome of Third Salvage Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2016, 128, 993-993.	0.6	9
18	Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse. <i>European Journal of Haematology</i> , 2016, 96, 119-127.	1.1	8

#	ARTICLE	IF	CITATIONS
19	BAL fluid analysis in the identification of infectious agents in patients with hematological malignancies and pulmonary infiltrates. <i>Folia Microbiologica</i> , 2020, 65, 109-120.	1.1	8
20	Oral manifestation of sarcoidosis: A case report and review of the literature. <i>Journal of Indian Society of Periodontology</i> , 2016, 20, 627.	0.3	8
21	Identification of patients at high risk of secondary extramedullary multiple myeloma development. <i>British Journal of Haematology</i> , 2021, , .	1.2	8
22	A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance. <i>European Journal of Haematology</i> , 2017, 99, 80-90.	1.1	7
23	Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2019, 187, 447-458.	1.2	7
24	Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies. <i>Cancer Medicine</i> , 2018, 7, 4132-4145.	1.3	6
25	Pneumocystis Pneumonia During Medicamentous Treatment of Cushing's Syndrome – A Description of Two Cases. <i>Acta Medica (Hradec Kralove)</i> , 2011, 54, 127-130.	0.2	6
26	Clinical and genotypic CMV drug resistance in HSCT recipients: a single center epidemiological and clinical data. <i>Bone Marrow Transplantation</i> , 2019, 54, 146-149.	1.3	4
27	Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma – analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies. <i>Neoplasma</i> , 2019, 66, 499-505.	0.7	4
28	Treatment of Relapsed and Refractory Multiple Myeloma with Fully Oral Triplet IRD (ixazomib,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 387 1959-1959.	0.6	4
29	Oral Mucositis Association with Periodontal Status: A Retrospective Analysis of 496 Patients Undergoing Hematopoietic Stem Cell Transplantation. <i>Journal of Clinical Medicine</i> , 2021, 10, 5790.	1.0	4
30	10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group. <i>Leukemia Research</i> , 2013, 37, 1063-1069.	0.4	3
31	NK/T-cell lymphoma nasal type with an unusual clinical course. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2014, 80, 564.	0.2	3
32	Human polyomavirus 9 in immunocompromised patients in the University Hospital in Hradec Kralove, Czech Republic. <i>Journal of Medical Virology</i> , 2017, 89, 2230-2234.	2.5	3
33	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 1885-1893.	0.6	3
34	The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?. <i>Blood</i> , 2018, 132, 4452-4452.	0.6	3
35	Multiple Myeloma R-ISS Prognostic Stratification System in Real Life Population. <i>Blood</i> , 2016, 128, 3333-3333.	0.6	3
36	Treatment of Multifocal Multisystem BRAF Positive Langerhans Cell Histiocytosis with Cladribine, Surgery and Allogenic Stem Cell Transplantation. <i>Acta Medica (Hradec Kralove)</i> , 2017, 60, 152-156.	0.2	3

#	ARTICLE	IF	CITATIONS
37	Ciprofloxacin prophylaxis during autologous stem cell transplantation for multiple myeloma in patients with a high rate of fluoroquinolone-resistant gram-negative bacteria colonization. Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia, 2019, 163, 161-165.	0.2	3
38	Plasmacytic Post-transplant Lymphoproliferative Disorder â€œ Case Report. European Oncology and Haematology, 2017, 13, 80.	0.0	3
39	Simplified novel prognostic score for real-life older adults with multiple myelomaâ€”registry-based analysis. Annals of Hematology, 2019, 98, 951-962.	0.8	2
40	Overall Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) over Lenalidomide and Dexamethasone (RD) in RRMM Patients Treated in Routine Clinical Practice: Results from the Czech Registry of Monoclonal Gammopathies (RMG). Blood, 2019, 134, 3139-3139.	0.6	2
41	FIFTEEN YEARS OF SINGLE CENTER EXPERIENCE WITH STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA: A RETROSPECTIVE ANALYSIS. Acta Medica (Hradec Kralove), 2013, 56, 9-13.	0.2	2
42	Detection of cytomegalovirus DNA in fecal samples in the diagnosis of enterocolitis after allogeneic stem cell transplantation. Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia, 2018, 162, 227-231.	0.2	2
43	Real-world comparison of Ixazomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in relapsed and refractory multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e271-e272.	0.2	1
44	Bortezomibâ€”based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data. European Journal of Haematology, 2021, 107, 466-474.	1.1	1
45	Urine immunofixation negativity is not necessary for complete response in intact immunoglobulin multiple myeloma: Retrospective realâ€”world confirmation. International Journal of Laboratory Hematology, 2021, 43, e244-e247.	0.7	1
46	Evaluation of Current Clinical Models for Risk of Progression from Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma or Related Malignancies in 2028 Persons Followed in the Czech Republic. Blood, 2014, 124, 3376-3376.	0.6	1
47	Simple Prognostic Score for Evaluation of Elderly Multiple Myeloma Patients. Blood, 2016, 128, 5679-5679.	0.6	1
48	Hematogenous Extramedullary Relapse in Multiple Myeloma - A Multicenter Retrospective Study in 127 Patients. Blood, 2018, 132, 2004-2004.	0.6	1
49	Oral Manifestations of Nutritional Deficiencies: Single Centre Analysis. Acta Medica (Hradec Kralove), 2020, 63, 95-100.	0.2	1
50	Prognostic factors affecting the outcome after allogeneic haematopoietic stem cell transplantation for myelodysplastic syndrome. Leukemia Research Reports, 2021, 16, 100274.	0.2	1
51	Follow-up Analysis of Ixazomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Routine Clinical Practice. Blood, 2021, 138, 2716-2716.	0.6	1
52	Improved laboratory diagnostics of Streptococcus pneumoniae in respiratory tract samples through qPCR. New Microbiologica, 2020, 43, 70-77.	0.1	1
53	Sequential Allogeneic Stem Cell Transplantation in High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2013, 19, S312.	2.0	0
54	Extracorporeal elimination in familial hypercholesterolemia â€œ comparison of two methods. Transfusion and Apheresis Science, 2014, 50, S18.	0.5	0

#	ARTICLE	IF	CITATIONS
55	Autologous stem cell collection after biosimilar G-CSF (Zarzio®) compared to original G-CSF (Neupogen®) in multiple myeloma patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e167.	0.2	0
56	Urine immunofixation is not necessary for CR definition in myeloma patients with complete M protein molecule. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e180-e181.	0.2	0
57	Registry of Monoclonal Gammopathies (RMG) - the monitored real-world database of the Czech Myeloma Group. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e324-e325.	0.2	0
58	High-Dose Therapy and Autologous Stem Cell Transplantation for Multiple Myeloma: Analysis from Registry of Monoclonal Gammopathy of Czech Myeloma Group. <i>Blood</i> , 2012, 120, 4528-4528.	0.6	0
59	Subcutaneous and Intravenous Bortezomib in Multiple Myeloma Patients Has Similar Response Rates and Toxicity Profile with No Difference in the Incidence of Peripheral Neuropathy: Report of the Czech Myeloma Group. <i>Blood</i> , 2014, 124, 2117-2117.	0.6	0
60	Stem Cell Mobilization after Various Induction Regimens in Patients with Multiple Myeloma. <i>Blood</i> , 2015, 126, 5433-5433.	0.6	0
61	Treatment Outcomes of Real Life Elderly Multiple Myeloma Patients: Analysis from Registry of Monoclonal Gammopathies (RMG). <i>Blood</i> , 2018, 132, 2019-2019.	0.6	0
62	Risk Factors Associated with Development of Extramedullary Disease in Multiple Myeloma. <i>Blood</i> , 2018, 132, 5596-5596.	0.6	0
63	EFFECTS OF FLUOROQUINOLONE RESTRICTION IN THE HOSPITAL ON THE DEVELOPMENT OF SENSITIVITY OF SELECTED BACTERIAL PATHOGENS. <i>Military Medical Science Letters (Vojenske Zdravotnicke Listy)</i> , 2020, 89, 178-189.	0.2	0
64	Iron Deficiency as Cause of Dysphagia and Burning Mouth (Plummer-Vinson or Kelly-Patterson) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 38	0.2	0
65	Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in Czech Republic. <i>Blood</i> , 2021, 138, 4894-4894.	0.6	0